Pacific Edge Beheer

Beheer criteriumcontroles 2/4

De CEO Pacific Edge is Peter Meintjes, benoemd in Jan2022, heeft een ambtstermijn van 2.83 jaar. bezit rechtstreeks 0.081% van de aandelen van het bedrijf, ter waarde NZ$ 91.87K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.1 jaar en 8.3 jaar.

Belangrijke informatie

Peter Meintjes

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	2.8yrs
Eigendom CEO	0.08%
Management gemiddelde ambtstermijn	3.1yrs
Gemiddelde ambtstermijn bestuur	8.3yrs

Recente managementupdates

Recent updates

Is Pacific Edge (NZSE:PEB) In A Good Position To Invest In Growth?

Nov 15

Further Upside For Pacific Edge Limited (NZSE:PEB) Shares Could Introduce Price Risks After 33% Bounce

Sep 16

Lacklustre Performance Is Driving Pacific Edge Limited's (NZSE:PEB) 30% Price Drop

Dec 18

Fewer Investors Than Expected Jumping On Pacific Edge Limited (NZSE:PEB)

Jun 06

Pacific Edge Limited (NZSE:PEB) Annual Results: Here's What Analysts Are Forecasting For This Year

May 27

We're Hopeful That Pacific Edge (NZSE:PEB) Will Use Its Cash Wisely

May 23

Companies Like Pacific Edge (NZSE:PEB) Are In A Position To Invest In Growth

Sep 06

Pacific Edge (NZSE:PEB) Is In A Good Position To Deliver On Growth Plans

May 31

Pacific Edge (NZSE:PEB) Is In A Strong Position To Grow Its Business

Jan 17

We're Hopeful That Pacific Edge (NZSE:PEB) Will Use Its Cash Wisely

Jun 05

Pacific Edge Limited (NZSE:PEB): Are Analysts Optimistic?

May 14

Don't Ignore The Fact That This Insider Just Sold Some Shares In Pacific Edge Limited (NZSE:PEB)

Mar 21

Did The Underlying Business Drive Pacific Edge's (NZSE:PEB) Lovely 750% Share Price Gain?

Mar 13

Have Insiders Been Selling Pacific Edge Limited (NZSE:PEB) Shares?

Feb 14

Pacific Edge Limited's (NZSE:PEB) Profit Outlook

Jan 18

How Much Of Pacific Edge Limited (NZSE:PEB) Do Insiders Own?

Dec 23

Did You Participate In Any Of Pacific Edge's (NZSE:PEB) Incredible 434% Return?

Nov 21

CEO

Peter Meintjes

2.8yrs

Tenure

Dr. Peter Meintjes served as a Chief Commercial Officer at Transplant Genomics, Inc., since April 2020. he serves as CEO at Pacific Edge Limited since January 17, 2022. He was responsible for leding the co...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Peter Meintjes	Chief Executive Officer	2.8yrs	geen gegevens	0.081% NZ$ 91.9k
Grant Gibson	Chief Financial Officer	4.9yrs	geen gegevens	0.020% NZ$ 23.0k
Darrell Morgan	Chief Operating Officer	2.1yrs	geen gegevens	geen gegevens
Justin Harvey	Chief Technology Officer	4.8yrs	geen gegevens	geen gegevens
Parry Guilford	Chief Scientific Officer & Member of Scientific Advisory Board	no data	NZ$134.00k	geen gegevens
Andrew McIntosh	Chief Digital Officer	3.4yrs	geen gegevens	geen gegevens
Glen Costin	President of Asia Pacific	no data	geen gegevens	geen gegevens
Tamer Aboushwareb	Chief Medical Officer	no data	geen gegevens	geen gegevens
David Levison	Executive Chairman & President of Pacific Edge Diagnostics USA	no data	NZ$53.00k	geen gegevens

3.1yrs

Gemiddelde duur

Ervaren management: Het managementteam van PEB wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.1 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Parry Guilford	Chief Scientific Officer & Member of Scientific Advisory Board	no data	NZ$134.00k	geen gegevens
David Levison	Executive Chairman & President of Pacific Edge Diagnostics USA	no data	NZ$53.00k	geen gegevens
R. Spence	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Chris Gallaher	Independent Non-Executive Chairman of the Board	8.3yrs	NZ$115.00k	0.12% NZ$ 140.0k
Osamu Ogawa	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Bryan Raymond Williams	Member of Scientific Advisory Board & Independent Deputy Non-Executive Chairman	11.4yrs	NZ$70.00k	0.075% NZ$ 85.4k
Michael Sullivan	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Nikola Kasabov	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Murray Brennan	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Anatole G. Masfen	Independent Non-Executive Director	16.6yrs	NZ$60.00k	1.15% NZ$ 1.3m
Anna Stove	Independent Non-Executive Director	3.7yrs	NZ$65.00k	0.00062% NZ$ 704.7
Sarah Park	Independent Non-Executive Director	5.9yrs	NZ$70.00k	0.0072% NZ$ 8.2k

8.3yrs

Gemiddelde duur

75yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van PEB wordt beschouwd als ervaren (gemiddelde ambtstermijn 8.3 jaar).

Pacific Edge Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Pacific Edge Limited, Annual General Meeting, Sep 24, 2024

Insufficient new directors

Pacific Edge Limited Announces Board Changes

Independent Non-Executive Director recently bought NZ$3.1m worth of stock

Key Executive recently bought NZ$54k worth of stock

Pacific Edge Limited Appoints Darrell Morgan as Chief Operating Officer

Recent updates

Is Pacific Edge (NZSE:PEB) In A Good Position To Invest In Growth?

Pacific Edge Limited to Report First Half, 2025 Results on Nov 26, 2024

Price target increased by 19% to NZ$0.15

New major risk - Share price stability

Further Upside For Pacific Edge Limited (NZSE:PEB) Shares Could Introduce Price Risks After 33% Bounce

Here's Why We're Watching Pacific Edge's (NZSE:PEB) Cash Burn Situation

Full year 2024 earnings released: NZ$0.036 loss per share (vs NZ$0.033 loss in FY 2023)

No longer forecast to breakeven

Pacific Edge Limited, Annual General Meeting, Sep 24, 2024

Pacific Edge Limited to Report Fiscal Year 2024 Results on May 21, 2024

Investors Holding Back On Pacific Edge Limited (NZSE:PEB)

Insufficient new directors

Pacific Edge Limited Announces Board Changes

Here's Why We're Watching Pacific Edge's (NZSE:PEB) Cash Burn Situation

Lacklustre Performance Is Driving Pacific Edge Limited's (NZSE:PEB) 30% Price Drop

Consensus EPS estimates upgraded to NZ$0.034 loss

First half 2024 earnings released: NZ$0.019 loss per share (vs NZ$0.013 loss in 1H 2023)

Pacific Edge Limited to Report First Half, 2024 Results on Nov 23, 2023

Price target decreased by 7.8% to NZ$0.15

Independent Non-Executive Director recently bought NZ$3.1m worth of stock

Key Executive recently bought NZ$54k worth of stock

Price target decreased by 34% to NZ$0.38

Pacific Edge Limited Announces Medicare Coverage of Cxbladder Tests in the US Market is Expected to Cease from 17 July 2023

Fewer Investors Than Expected Jumping On Pacific Edge Limited (NZSE:PEB)

Pacific Edge Limited (NZSE:PEB) Annual Results: Here's What Analysts Are Forecasting For This Year

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Forecast to breakeven in 2026

We're Hopeful That Pacific Edge (NZSE:PEB) Will Use Its Cash Wisely

Pacific Edge Announces the Acceptance for Publication of New Clinical Evidence That Shows Significant Improvements in the Performance of its Genomic Diagnostic Cxbladder Tests

Consensus forecasts updated

First half 2023 earnings released: NZ$0.013 loss per share (vs NZ$0.012 loss in 1H 2022)

Price target decreased to NZ$0.61

Companies Like Pacific Edge (NZSE:PEB) Are In A Position To Invest In Growth

Price target decreased to NZ$0.72

Pacific Edge Limited Appoints Darrell Morgan as Chief Operating Officer

Pacific Edge Limited to Report First Half, 2023 Results on Nov 26, 2022

Consensus revenue estimates fall by 27%

Pacific Edge (NZSE:PEB) Is In A Good Position To Deliver On Growth Plans

Now 26% undervalued after recent price drop

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to NZ$1.11

Pacific Edge Limited Announces It Is Advancing Its Clinical Evidence Generation Program with Lobster

Insufficient new directors

Consensus forecasts updated

Price target decreased to NZ$1.32

Pacific Edge (NZSE:PEB) Is In A Strong Position To Grow Its Business

Insufficient new directors

Consensus revenue estimates fall to NZ$12.9m

First half 2022 earnings: EPS and revenues exceed analyst expectations

No longer forecast to breakeven

CEO, MD & Executive Director exercised options to buy NZ$478k worth of stock.

Consensus EPS estimates fall to -NZ$0.014

We're Hopeful That Pacific Edge (NZSE:PEB) Will Use Its Cash Wisely

Full year 2021 earnings released: NZ$0.02 loss per share (vs NZ$0.032 loss in FY 2020)

Pacific Edge Limited (NZSE:PEB): Are Analysts Optimistic?

Insider recently sold NZ$130k worth of stock

Don't Ignore The Fact That This Insider Just Sold Some Shares In Pacific Edge Limited (NZSE:PEB)

Insider recently sold NZ$120k worth of stock

Did The Underlying Business Drive Pacific Edge's (NZSE:PEB) Lovely 750% Share Price Gain?

Have Insiders Been Selling Pacific Edge Limited (NZSE:PEB) Shares?

Analysts update estimates

Pacific Edge Limited's (NZSE:PEB) Profit Outlook

Pacific Edge Limited, Annual General Meeting, Jul 29, 2021

Pacific Edge Limited to Report First Half, 2022 Results on Nov 26, 2021

How Much Of Pacific Edge Limited (NZSE:PEB) Do Insiders Own?

New 90-day high: NZ$1.08

New 90-day high: NZ$0.78

First half 2021 earnings released: NZ$0.01 loss per share